Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12D Mutation”

58 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 58 results

Large-scale testing (Phase 3)Looking for participantsNCT07409272
What this trial is testing

Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Who this might be right for
Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 614
Early research (Phase 1)Looking for participantsNCT06179160
What this trial is testing

Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Incyte Corporation 710
Testing effectiveness (Phase 2)Looking for participantsNCT06667544
What this trial is testing

RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

Who this might be right for
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd. 152
Early research (Phase 1)Looking for participantsNCT06227377
What this trial is testing

QTX3034 in Patients With KRAS G12D Mutation

Who this might be right for
Solid Tumors
Quanta Therapeutics 250
Early research (Phase 1)Active Not RecruitingNCT06428500
What this trial is testing

QTX3046 in Patients With KRAS G12D Mutations

Who this might be right for
Advanced Solid Tumor
Quanta Therapeutics 240
Early research (Phase 1)Looking for participantsNCT07134998
What this trial is testing

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 153
Testing effectiveness (Phase 2)Looking for participantsNCT07438106
What this trial is testing

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Who this might be right for
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University 30
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Early research (Phase 1)Looking for participantsNCT06619587
What this trial is testing

Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Genentech, Inc. 410
Testing effectiveness (Phase 2)Ended earlyNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT06385925
What this trial is testing

TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited 440
Testing effectiveness (Phase 2)Looking for participantsNCT06500676
What this trial is testing

GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Who this might be right for
KRAS G12D MutationsAdvanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc. 407
Testing effectiveness (Phase 2)Looking for participantsNCT07259590
What this trial is testing

GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced Solid Tumors CancerPDACCRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc. 126
Early research (Phase 1)Looking for participantsNCT05382559
What this trial is testing

ASP3082 in Adults With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Astellas Pharma Inc 681
Testing effectiveness (Phase 2)Looking for participantsNCT06770452
What this trial is testing

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Who this might be right for
Metastatic Pancreatic Carcinoma
Zhejiang University 133
Early research (Phase 1)Looking for participantsNCT06487377
What this trial is testing

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

Who this might be right for
Pancreatic CancerColorectal Cancer
Shanghai Pudong Hospital 12
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Looking for participantsNCT06445062
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Who this might be right for
Colorectal CancerCRCPancreatic Ductal Adenocarcinoma+3 more
Revolution Medicines, Inc. 1,130
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385678
What this trial is testing

HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Who this might be right for
Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 47
Load More Results